Emetine and the alternative splicing of Bcl-X: where to next?
Interference with the alternative splicing of apoptotic factors offers an innovative and specific mechanism to target malignant cells. In this issue of Chemistry & Biology, Zhou et al. report on the regulation of the alternative splicing of Bcl-x pre-mRNA in response to emetine, a potent protein synthesis inhibitor, as well as define a major player in the signaling mechanism.
Shultz
Jacqueline C
JC
Department of Biochemistry, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0614, USA.
Chalfant
Charles E
CE
D017398:Alternative Splicing / Q000187:drug effects*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D004640:Emetine / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D054645:Protein Phosphatase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D051020:bcl-X Protein / Q000235:genetics*
D004791:Enzyme Inhibitors; D051020:bcl-X Protein; D054645:Protein Phosphatase 1; D004640:Emetine